French biopharmaceutical company Poxel SA (EPA: POXEL) is poised to present data from the Imeglimin Phase 2b study conducted in Japan, the company confirmed on Thursday.

Poxel, whose primary focus is on the development of innovative therapies for metabolic disorders, will share the results at the European Association for the Study of Diabetes 53rd Annual Meeting, held at the International Fair of Lisbon, Portugal.

The Phase 2b randomised, double-blind, placebo-controlled study examined the drug's efficacy in treating type 2 diabetes.

"The strong efficacy and favourable safety profile of Imeglimin observed in this study suggests that it could be particularly well-suited for Japanese patients," said Professor Kohjiro Ueki, MD, PhD, director of the Diabetes Research Centre, Research Institute, National Centre for Global Health and Medicine, Tokyo, Japan.

"Diabetes is a growing health concern in Asia and Imeglimin has the potential to become an innovative new treatment option for Japanese patients to manage their type 2 diabetes."